Herein, we present the results of a translational analysis of sTILs using tumor samples from the WSG PlanB trial, which compared an anthracycline-free chemotherapy regimen (6 x docetaxel/cyclophosphamide, TC) to an anthracycline-taxane sequence (4xEC ➔ 4xDoc) among patients with HER2-negative EBC. This evidence concerns the gene ERBB2 and neoplasm.